With more than 10% of all AMLs demonstrating EVI1 overexpression, and this phenomenon correlating with poor prognosis, it would clearly be desirable to develop targeted therapies to effectively treat these EVI1high leukemias; both in the setting of 3q rearrangements, as well as the more frequent non-3q rearranged EVI1high AMLs. Here, MECOM is linked to leukemia.